Search Results
Showing Results for Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...
Key highlights from the 10th Congress of the European Academy of Neurology (EAN) in Helsinki (EAN2024).
Welcome to the latest edition of touchREVIEWS in Neurology, featuring a range of interviews, reviews and reports on some of the key recent developments in neurological disease. We open with three expert interviews with key members of the pan-European organisation, ...
Hirayama disease (HD) is a lower motor neurologic disorder that manifests in young males in their early 20s, manifesting with gradually progressive weakness and wasting of C7-T1 innervated muscles. Dynamic magnetic resonance imaging (MRI) clinches the diagnosis, and treatment ...
Welcome to the latest edition of touchREVIEWS in Neurology, which features a diverse range of topical articles covering therapeutic areas relevant to neurologists and other practitioners involved in the care of patients with neurological illness. We begin with an editorial ...
Welcome to our new issue of touchREVIEWS in Neurology. This journal aims to review a wide range of topical subjects in the field of neurology. Articles have been chosen for their evaluation of current practices and research, and their discussion ...
touchNEUROLOGY met up with Prof. Giuseppe Lauria Pinter (University of Milan, Milan, Italy) to discuss the efficacy and outcome measures of a phase 2 study investigating guanabenz for the treatment of amyotrophic lateral sclerosis. The abstract entitled: ‘The unfolded protein response ...
Welcome to touchREVIEWS in Neurology, our newly-named journal, previously US Neurology. The decision to expand the scope of the journal was taken after an excellent year for touchNEUROLOGY. We feel that in an increasingly global research community, submissions were limited ...
It was a pleasure to interview Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss treatment options for the management of amyotrophic lateral sclerosis (ALS). The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ...
It was a pleasure to meet with Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss the CENTAUR study findings, and where AMX0035 is likely to be placed in the treatment paradigm for amyotrophic lateral sclerosis (ALS). The abstract ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that displays heterogeneous age of onset, symptoms, and progression.1,2Â The disease presents clinically with upper and lower motor neuron features.3Â There is no definitive test or assay that can be used ...
Welcome to the latest edition of US Neurology, which features a diverse range of topical articles covering a range of therapeutic areas relevant to neurologists and other practitioners involved in the care of patients with neurological illness. We begin with ...
The World Congress on Controversies in Neurology (CONy) provides a platform for international experts to discuss and compare experiences. Its debate-style structure bridges the gap between the latest scientific advances and their dissemination and use. The congress has become a ...
In the past 4 months, a novel coronavirus originating in Wuhan, China, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has affected more than 200 countries. As of mid-June 2020, there are over 7 million confirmed cases and more than 425,888 deaths worldwide caused by the novel ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
